Biora reports Q1 net loss $4.2M, completes BT-600 dosing, results expected late Q2

BIORA THERAPEUTICS, INC.

2024-Q1 EPS reported -$0.14 revenue$542,000

Net loss $4.2M ($0.14/share) vs $17.4M ($1.59) in Q1 2023; operating expenses $16.1M.
BT-600 Phase 1 trial fully dosed; SAD data showed colon delivery and lower plasma levels than oral tofacitinib.
BioJet platform animal studies demonstrate >15% bioavailability; partnering process targeting mid-2024.
Capital raised $19.8M new investment since Dec 2023, reduced $80M notes; $6M direct placement closed April 2024.
Topline BT-600 data expected late June 2024; NaviCap device data presented at DDW May 19.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BIORA THERAPEUTICS, INC. reported the first quarter ended March 31, 2024 results: net income Net loss was $4.2 million, EPS net loss per share was $0.14.

Period: the first quarter ended March 31, 2024
Net income: Net loss was $4.2 million
EPS: net loss per share was $0.14
Result: reported results

Exact text from the filing

Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

View on SEC.gov

Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-060453

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.